Joo HJ, et al. - Researchers determined the effect of hyperuricemia on long-term clinical outcomes following percutaneous coronary intervention (PCI) for in-stent restenosis (ISR). Patients who underwent repeat PCI for ISR from January 2009 to July 2015 were divided into the normal uric acid (UA) group and the higher UA group (those with serum UA levels > 6.8 mg/dL or who were taking anti-hyperuricemic medication). They carried out a median follow-up period of 1,088 days, during which they noted both groups showed similar cumulative incidence rates of major adverse event (MAE), including a composite of all-cause death, non-fatal myocardial infarction, and any revascularization. Overall, findings showed no association of hyperuricemia with poor clinical outcomes after repeat PCI for ISR lesions.